Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Malaysia | 24 | 2020 | 1116 | 0.92 | Why? |
| HIV Infections | 25 | 2021 | 11620 | 0.82 | Why? |
| Ethnic Cleansing | 1 | 2017 | 2 | 0.73 | Why? |
| Aging, Premature | 1 | 2017 | 11 | 0.71 | Why? |
| Prisoners | 3 | 2019 | 738 | 0.57 | Why? |
| Armed Conflicts | 1 | 2017 | 209 | 0.53 | Why? |
| Altruism | 1 | 2017 | 300 | 0.53 | Why? |
| Crowding | 1 | 2018 | 731 | 0.45 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.45 | Why? |
| Substance Abuse, Intravenous | 4 | 2017 | 411 | 0.45 | Why? |
| Islam | 1 | 2017 | 545 | 0.43 | Why? |
| Antiretroviral Therapy, Highly Active | 7 | 2018 | 952 | 0.42 | Why? |
| Anti-HIV Agents | 7 | 2018 | 2209 | 0.42 | Why? |
| Prisons | 3 | 2019 | 980 | 0.40 | Why? |
| Human Rights | 1 | 2017 | 618 | 0.40 | Why? |
| Transgender Persons | 3 | 2017 | 322 | 0.38 | Why? |
| Metabolic Syndrome | 1 | 2017 | 810 | 0.37 | Why? |
| Refugees | 1 | 2017 | 809 | 0.34 | Why? |
| Tuberculosis | 2 | 2021 | 2895 | 0.30 | Why? |
| Genotype | 7 | 2018 | 4697 | 0.28 | Why? |
| Drug Users | 2 | 2017 | 234 | 0.25 | Why? |
| Sex Workers | 2 | 2017 | 348 | 0.25 | Why? |
| Opiate Substitution Treatment | 3 | 2019 | 613 | 0.24 | Why? |
| Developing Countries | 2 | 2017 | 4283 | 0.23 | Why? |
| HIV-1 | 5 | 2016 | 3365 | 0.21 | Why? |
| Criminal Law | 2 | 2018 | 84 | 0.21 | Why? |
| Methadone | 3 | 2019 | 296 | 0.20 | Why? |
| Fusobacterium | 1 | 2018 | 19 | 0.19 | Why? |
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2018 | 4 | 0.19 | Why? |
| Cost of Illness | 2 | 2021 | 1903 | 0.19 | Why? |
| Asia | 5 | 2018 | 2399 | 0.18 | Why? |
| Genetic Variation | 6 | 2020 | 3919 | 0.18 | Why? |
| Coronavirus OC43, Human | 2 | 2017 | 1157 | 0.18 | Why? |
| Voluntary Programs | 1 | 2017 | 22 | 0.17 | Why? |
| Behavior Therapy | 2 | 2019 | 235 | 0.17 | Why? |
| Involuntary Treatment | 1 | 2017 | 30 | 0.17 | Why? |
| Drug Resistance, Viral | 2 | 2016 | 1083 | 0.17 | Why? |
| Myanmar | 1 | 2017 | 234 | 0.16 | Why? |
| Executive Function | 1 | 2018 | 173 | 0.16 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 203 | 0.16 | Why? |
| Respiratory Tract Infections | 4 | 2018 | 6817 | 0.16 | Why? |
| Social Control Policies | 1 | 2016 | 54 | 0.15 | Why? |
| Financial Support | 1 | 2017 | 170 | 0.15 | Why? |
| Hypertriglyceridemia | 1 | 2017 | 90 | 0.15 | Why? |
| Platelet Transfusion | 1 | 2017 | 209 | 0.15 | Why? |
| Metapneumovirus | 1 | 2018 | 465 | 0.15 | Why? |
| Paramyxoviridae Infections | 1 | 2018 | 364 | 0.14 | Why? |
| South America | 1 | 2017 | 565 | 0.14 | Why? |
| Chlamydia Infections | 1 | 2017 | 248 | 0.14 | Why? |
| Risk-Taking | 2 | 2016 | 508 | 0.14 | Why? |
| Neuraminidase | 1 | 2017 | 289 | 0.14 | Why? |
| Evolution, Molecular | 5 | 2017 | 3691 | 0.14 | Why? |
| Drug and Narcotic Control | 1 | 2016 | 134 | 0.14 | Why? |
| Substance-Related Disorders | 3 | 2018 | 2038 | 0.14 | Why? |
| Herpes Simplex | 1 | 2017 | 272 | 0.13 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.13 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 533 | 0.13 | Why? |
| Gonorrhea | 1 | 2017 | 315 | 0.13 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.13 | Why? |
| Viral Load | 5 | 2018 | 15850 | 0.13 | Why? |
| Syphilis | 1 | 2017 | 318 | 0.13 | Why? |
| Neuropsychological Tests | 1 | 2018 | 954 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.12 | Why? |
| Immunosenescence | 1 | 2015 | 169 | 0.12 | Why? |
| Picornaviridae Infections | 1 | 2018 | 544 | 0.12 | Why? |
| Sarcopenia | 1 | 2018 | 422 | 0.12 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2017 | 511 | 0.12 | Why? |
| Prevalence | 8 | 2018 | 25773 | 0.12 | Why? |
| Phylogeography | 1 | 2017 | 824 | 0.12 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.12 | Why? |
| Rhinovirus | 1 | 2018 | 979 | 0.12 | Why? |
| Cellular Senescence | 1 | 2015 | 326 | 0.12 | Why? |
| Social Stigma | 2 | 2017 | 1049 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.11 | Why? |
| Adult | 28 | 2019 | 244371 | 0.11 | Why? |
| Influenza B virus | 1 | 2017 | 815 | 0.11 | Why? |
| Recombination, Genetic | 3 | 2017 | 1265 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Coronavirus NL63, Human | 1 | 2016 | 669 | 0.10 | Why? |
| Common Cold | 1 | 2016 | 645 | 0.10 | Why? |
| Phylogeny | 9 | 2020 | 13341 | 0.10 | Why? |
| Public Health Surveillance | 2 | 2020 | 3129 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2018 | 5837 | 0.10 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.10 | Why? |
| Quality of Health Care | 1 | 2021 | 1948 | 0.09 | Why? |
| Immune System | 1 | 2018 | 1479 | 0.09 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.09 | Why? |
| Intention | 1 | 2017 | 1380 | 0.09 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.09 | Why? |
| Humans | 47 | 2021 | 930598 | 0.09 | Why? |
| Africa | 1 | 2017 | 2986 | 0.09 | Why? |
| Male | 30 | 2019 | 367725 | 0.09 | Why? |
| Coronavirus 229E, Human | 1 | 2016 | 1241 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Mutation | 4 | 2020 | 12376 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.08 | Why? |
| Opioid-Related Disorders | 1 | 2019 | 1185 | 0.08 | Why? |
| Biosensing Techniques | 1 | 2021 | 2116 | 0.08 | Why? |
| Urban Population | 1 | 2017 | 2000 | 0.08 | Why? |
| Molecular Epidemiology | 3 | 2018 | 1638 | 0.08 | Why? |
| Female | 27 | 2018 | 380317 | 0.08 | Why? |
| Substance Abuse Treatment Centers | 2 | 2017 | 106 | 0.07 | Why? |
| Mutation, Missense | 1 | 2011 | 863 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Academic Medical Centers | 1 | 2017 | 3088 | 0.07 | Why? |
| Tuberculosis, Pulmonary | 1 | 2015 | 1171 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| Dengue | 1 | 2017 | 1565 | 0.07 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.07 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Middle Aged | 20 | 2019 | 270681 | 0.06 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.06 | Why? |
| Internationality | 1 | 2016 | 3297 | 0.06 | Why? |
| Sequence Analysis | 2 | 2018 | 496 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Genome, Viral | 5 | 2020 | 13157 | 0.06 | Why? |
| Dielectric Spectroscopy | 1 | 2021 | 75 | 0.05 | Why? |
| Naphthyridines | 1 | 2020 | 48 | 0.05 | Why? |
| RNA, Viral | 6 | 2020 | 32276 | 0.05 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Coinfection | 2 | 2017 | 6820 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.05 | Why? |
| Asia, Southeastern | 1 | 2020 | 390 | 0.05 | Why? |
| Cluster Analysis | 2 | 2018 | 3001 | 0.05 | Why? |
| Nasopharynx | 4 | 2020 | 10224 | 0.05 | Why? |
| Sexual Behavior | 2 | 2018 | 1322 | 0.05 | Why? |
| Epidemiologic Studies | 1 | 2021 | 554 | 0.05 | Why? |
| Artemisinins | 1 | 2020 | 238 | 0.05 | Why? |
| Linear Models | 2 | 2018 | 1914 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Walking Speed | 1 | 2018 | 77 | 0.04 | Why? |
| Transsexualism | 1 | 2017 | 43 | 0.04 | Why? |
| Thailand | 2 | 2014 | 1155 | 0.04 | Why? |
| Disease Transmission, Infectious | 2 | 2018 | 9044 | 0.04 | Why? |
| Tablets | 1 | 2018 | 219 | 0.04 | Why? |
| Mental Status and Dementia Tests | 1 | 2018 | 208 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 8811 | 0.04 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.04 | Why? |
| Dideoxynucleosides | 1 | 2017 | 92 | 0.04 | Why? |
| Rilpivirine | 1 | 2017 | 65 | 0.04 | Why? |
| Genes, Viral | 2 | 2016 | 1428 | 0.04 | Why? |
| Narcotics | 1 | 2017 | 67 | 0.04 | Why? |
| Lymphocyte Activation | 2 | 2018 | 2742 | 0.04 | Why? |
| Unsafe Sex | 1 | 2017 | 139 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2017 | 242 | 0.04 | Why? |
| Kynurenine | 1 | 2017 | 140 | 0.04 | Why? |
| British Columbia | 1 | 2018 | 512 | 0.04 | Why? |
| Sampling Studies | 1 | 2017 | 386 | 0.04 | Why? |
| Interleukin-7 Receptor alpha Subunit | 1 | 2015 | 13 | 0.04 | Why? |
| Condoms | 1 | 2017 | 235 | 0.04 | Why? |
| HLA-DR alpha-Chains | 1 | 2015 | 8 | 0.04 | Why? |
| Tryptophan | 1 | 2017 | 218 | 0.04 | Why? |
| CD57 Antigens | 1 | 2015 | 96 | 0.04 | Why? |
| Mucous Membrane | 1 | 2018 | 305 | 0.04 | Why? |
| AIDS Vaccines | 1 | 2020 | 452 | 0.04 | Why? |
| Metabolic Networks and Pathways | 1 | 2017 | 285 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.04 | Why? |
| Models, Economic | 1 | 2018 | 316 | 0.04 | Why? |
| Muscle Strength | 1 | 2018 | 317 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.04 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 96 | 0.04 | Why? |
| Sequence Homology | 1 | 2017 | 448 | 0.04 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.04 | Why? |
| Retroviridae Proteins | 1 | 2014 | 5 | 0.04 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.04 | Why? |
| Granzymes | 1 | 2015 | 197 | 0.04 | Why? |
| Perforin | 1 | 2015 | 136 | 0.04 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.04 | Why? |
| Reassortant Viruses | 1 | 2017 | 287 | 0.03 | Why? |
| CD4-CD8 Ratio | 1 | 2015 | 235 | 0.03 | Why? |
| Law Enforcement | 1 | 2016 | 113 | 0.03 | Why? |
| Prejudice | 1 | 2017 | 245 | 0.03 | Why? |
| Herpesvirus 1, Human | 1 | 2017 | 286 | 0.03 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.03 | Why? |
| Child | 3 | 2018 | 70012 | 0.03 | Why? |
| United Nations | 1 | 2016 | 367 | 0.03 | Why? |
| Hepatitis, Viral, Human | 1 | 2016 | 196 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2019 | 43792 | 0.03 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.03 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Awareness | 1 | 2017 | 529 | 0.03 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.03 | Why? |
| Aged | 9 | 2018 | 215776 | 0.03 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Community Health Services | 1 | 2021 | 1000 | 0.03 | Why? |
| Young Adult | 6 | 2018 | 93724 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Evidence-Based Practice | 1 | 2017 | 693 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2017 | 1182 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Treatment Failure | 1 | 2016 | 2106 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2016 | 925 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2018 | 1609 | 0.02 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.02 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2018 | 1158 | 0.02 | Why? |
| Cross-Sectional Studies | 4 | 2017 | 53120 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Cell Differentiation | 1 | 2015 | 1338 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2014 | 3198 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Cell Proliferation | 1 | 2015 | 1973 | 0.02 | Why? |
| Geography | 1 | 2014 | 1801 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2018 | 88759 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Mass Screening | 2 | 2017 | 8005 | 0.02 | Why? |
| Singapore | 1 | 2017 | 3641 | 0.02 | Why? |
| Equipment Contamination | 1 | 2016 | 1308 | 0.02 | Why? |
| Congresses as Topic | 1 | 2016 | 1347 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Membrane Glycoproteins | 1 | 2015 | 2273 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.02 | Why? |
| Employment | 1 | 2017 | 1754 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.02 | Why? |
| Computational Biology | 1 | 2020 | 4514 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.02 | Why? |
| Interferon-gamma | 1 | 2015 | 2711 | 0.02 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.02 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Serologic Tests | 1 | 2017 | 4359 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Hong Kong | 1 | 2011 | 3361 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Treatment Outcome | 2 | 2017 | 51732 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Population Surveillance | 1 | 2016 | 4967 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.01 | Why? |
| Logistic Models | 1 | 2013 | 9089 | 0.01 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.01 | Why? |
| Viral Proteins | 1 | 2016 | 7370 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2015 | 5002 | 0.01 | Why? |
| Disease Progression | 1 | 2015 | 13580 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2016 | 10697 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Public Health | 1 | 2016 | 16359 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2017 | 51949 | 0.00 | Why? |
Kamarulzaman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(270)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(125)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_